ISSN:0378-584X    

DOI:10.1159/000216450

出版商:S. Karger GmbH    

年代:1987

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000216355

出版商:S. Karger GmbH    

年代:1987

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000216451

出版商:S. Karger GmbH    

年代:1987

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000216452

出版商:S. Karger GmbH    

年代:1987

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000216453

出版商:S. Karger GmbH    

年代:1987

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000216358

出版商:S. Karger GmbH    

年代:1987

数据来源: Karger

摘要:

In a clinical phase-II study 11 patients with refractory ALL were treated with high-dose AraC and mitoxantrone in combination (HAM). Refractoriness was defined as: 1. primary resistance against the BMFTinduction protocol; 2. first relapse with non-response to the B-ALL/NHL regimen as salvage treatment; 3. second and subsequent relapses. Therapy consisted of HD-AraC 3 g/m2 every 12 h by a 3-h infusion on days 1–4 and mitoxantrone 10 mg/m2/d on days 2–6. Seven of the 11 patients achieved a complete remission, 1 patient was refractory against 2 HAM cycles and 3 patients died during bone marrow aplasia. Toxicity was acceptable, consisting mainly of nausea and vomiting, mucositis and diarrhea. One patient who had completed the prophylactic CNS treatment with intrathecal MTX and cranial irradiation immediately before entering the HAM protocol developed severe signs of cerebral toxicity. These data indicate a significant activity of HAM in refractory ALL and suggest that the combination should be applied at earlier stages of ALL treatm

ISSN:0378-584X    

DOI:10.1159/000216359

出版商:S. Karger GmbH    

年代:1987

数据来源: Karger

摘要:

Die randomisierte, multizentrische bundesdeutsche Studie 1982 zeigt nach TAD9-Induktion und Konsolidierung einen klaren, signifikanten Vorteil der Remissionsdauer und weniger ausgeprägt auch des Überlebens durch monatliche myelosuppressive Erhaltungs-Chemotherapie. Nach TAD9-Induktion und unter monatlicher Erhaltungs-Chemotherapie ergab zusätzliche Immuntherapie mitt els hochdosierter, Neuraminidase-behandelter allogeneischer Blasten keinen eindeutigen Vorteil der Remissionsdauer und des Überlebens. In der Pilotstudie 1985 bei Patienten unter 60 Jahren erwies sich das neue Konzept der Doppelinduktion mit Konsolidierung und monatlicher Erhaltung anhand der Remissionsrate (77%) und Frühletalität (12%) als gut praktikabel. Remissionsdauer und Überlebenszeit, projiziert auf l½ Jahre, erscheinen bisher

ISSN:0378-584X    

DOI:10.1159/000216360

出版商:S. Karger GmbH    

年代:1987

数据来源: Karger

摘要:

Thirteen patients (7 male, 9 female) aged 22 bis 71 years (x = 55 years) with acute non-lymphocytic leukemia and contraindications for anthracyclin therapy were treated with combined chemotherapy using m-amsacrine primarily or in relapse. The main reasons for avoiding cardiotoxic substances were overt cardiac insufficiency and former administration of daunorubicin with more than 540 mg/m2 body surface area. Amsacrine was combined with 6-thioguanine, VP 16–213 and cytosine arabinoside in conventional or high dosage. Eight out of 13 patients (62%) achieved complete remission after one or two courses of chemotherapy. One patient showed partial remission and could be brought into complete remission with another chemotherapy using high-dose ara-C and mitoxantrone. Three patients died in aplasia after chemotherapy and 1 other patient had to be regarded as a complete non-responder. Remission duration and survival time for the 8 successfully-treated patients so far is 1–12 months; however, medians have not yet been reached, since only one of the eight patients relapsed after 6 months of complete remission. These data indicate a high efficacy of m-amsacrine in combined chemotherapy for acute non-lymphocytic leukemia in high-risk patients with contraindications for anthracycl

ISSN:0378-584X    

DOI:10.1159/000216361

出版商:S. Karger GmbH    

年代:1987

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000216362

出版商:S. Karger GmbH    

年代:1987

数据来源: Karger